| Literature DB >> 35050015 |
Kustrim Cerimi1, Udo Jäckel1, Vera Meyer2, Ugarit Daher3, Jessica Reinert1, Stefanie Klar1.
Abstract
Microbial volatile organic compounds (mVOC) are metabolic products and by-products of bacteria and fungi. They play an important role in the biosphere: They are responsible for inter- and intra-species communication and can positively or negatively affect growth in plants. But they can also cause discomfort and disease symptoms in humans. Although a link between mVOCs and respiratory health symptoms in humans has been demonstrated by numerous studies, standardized test systems for evaluating the toxicity of mVOCs are currently not available. Also, mVOCs are not considered systematically at regulatory level. We therefore performed a literature survey of existing in vitro exposure systems and lung models in order to summarize the state-of-the-art and discuss their suitability for understanding the potential toxic effects of mVOCs on human health. We present a review of submerged cultivation, air-liquid-interface (ALI), spheroids and organoids as well as multi-organ approaches and compare their advantages and disadvantages. Furthermore, we discuss the limitations of mVOC fingerprinting. However, given the most recent developments in the field, we expect that there will soon be adequate models of the human respiratory tract and its response to mVOCs.Entities:
Keywords: In vitro toxicology; fingerprinting; in vitro exposure system; microbial volatile organic compounds; organoids; respiratory health
Year: 2022 PMID: 35050015 PMCID: PMC8780961 DOI: 10.3390/jof8010075
Source DB: PubMed Journal: J Fungi (Basel) ISSN: 2309-608X
Overview of studies regarding respiratory-health related symptoms with microbial volatile organic compounds.
| Study | Methods (Summary) | References |
|---|---|---|
| Walinder et al. | Experimental study with exposition chamber | [ |
| Araki et al. | Health outcome ascertainment coupled with GC/MS mVOC analysis | [ |
| Saijo et al. | Health outcome ascertainment and air sampling | [ |
| Araki et al. | Health outcome ascertainment coupled with GC/MS mVOC analysis | [ |
| Zhang et al. | Health outcome ascertainment and air sampling | [ |
| Sahlberg et al. | Health outcome ascertainment coupled with GC/MS mVOC analysis | [ |
| Choi et al. | Health outcome ascertainment and air sampling | [ |
Figure 1Cell composition along a bronchiole within the large airways. Ciliated epithelial cells (beige), mucus producing goblet cells (green), secretory cells (red) and basal progenitor cells (blue). Created with BioRender.com, accessed on 20 August 2021.
Figure 2Biological models and approaches to studying in vitro toxicity of microbial volatile organic substances (mVOCs). From left to right: Submerged system, single-cell air-liquid interface (ALI), multi-cell air-liquid interface (ALI), organoids and multi-organ chip approach, Created with BioRender.com, accessed on 20 August 2021.
Overview of respiratory cell lines and use in VOC or mVOC studies.
| Airway Cell Line | Source Material | Method of Immortalization | References Material | Used in VOC or mVOC Analysis |
|---|---|---|---|---|
| A549 | Epithelial adenocarcinoma | Tumor derived | [ | Yes [ |
| Calu-3 | Epithelial adenocarcinoma | Tumor derived | [ | Yes [ |
| BEAS-2B | Bronchial epithelium | SV40 T-antigen | [ | Yes [ |
| 16HBE14o- | Bronchial epithelium | SV40 T-antigen | [ | Yes [ |
| NuLi-1 | Bronchial epithelium | hTERT | [ | Yes [ |
| HBEC3-KT | Bronchial epithelium | hTERT | [ | No |
| BCi-NS1.1 | Large airways basal cell | hTERT | [ | No |
| hAELVI | Primary alveolar epithelim | Lentivirus | [ | Yes [ |
| hSABCi-NS1.1 | Small airway basal cell | hTERT | [ | No |
Figure 3Biological model systems comparisons between physiological relevance and requirements. Submerged system, Single-cell Air-liquid interface (ALI), Multi-cell Air-liquid interface (ALI), Organoids and Multi-organ chip approach (from left to right). Created with BioRender.com, accessed on 20 August 2021.